Pathogenesis, prevention, and treatment of diabetic nephropathy
- PMID: 9683226
- DOI: 10.1016/S0140-6736(98)01346-4
Pathogenesis, prevention, and treatment of diabetic nephropathy
Abstract
It is likely that the pathophysiology of diabetic nephropathy involves an interaction of metabolic and haemodynamic factors. Relevant metabolic factors include glucose-dependent pathways such as advanced glycation, increased formation of polyols, and activation of the enzyme, protein kinase C. Specific inhibitors of the various pathways are now available, enabling investigation of the role of these processes in the pathogenesis of diabetic nephropathy and potentially to provide new therapeutic approaches for the prevention and treatment of diabetic nephropathy. Haemodynamic factors to consider include systemic hypertension, intraglomerular hypertension, and the role of vasoactive hormones, such as angiotensin II. The mainstay of therapy remains attaining optimum glycaemic control. Antihypertensive therapy has a major role in slowing the progression of diabetic nephropathy. Agents that interrupt the renin-angiotensin system such as angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists may be particularly useful as renoprotective agents in both the hypertensive and normotensive context.
Similar articles
-
[Risk and prevention of diabetic nephropathy].G Ital Nefrol. 2007 Sep-Oct;24 Suppl 38:13-9. G Ital Nefrol. 2007. PMID: 17922442 Italian.
-
Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy.Diabetologia. 2001 Nov;44(11):1957-72. doi: 10.1007/s001250100000. Diabetologia. 2001. PMID: 11719827 Review.
-
Management of nephropathy in patients with type 2 diabetes.Chin Med J (Engl). 2002 Jan;115(1):129-35. Chin Med J (Engl). 2002. PMID: 11930647 Review.
-
Losartan in diabetic nephropathy.Expert Rev Cardiovasc Ther. 2004 Jul;2(4):473-83. doi: 10.1586/14779072.2.4.473. Expert Rev Cardiovasc Ther. 2004. PMID: 15225108 Review.
-
Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy.Curr Hypertens Rep. 2002 Oct;4(5):387-93. doi: 10.1007/s11906-002-0069-3. Curr Hypertens Rep. 2002. PMID: 12217258 Review.
Cited by
-
Treatment of hypertension in diabetic patients with nephropathy.Curr Diab Rep. 2001 Dec;1(3):251-60. doi: 10.1007/s11892-001-0043-5. Curr Diab Rep. 2001. PMID: 12643207 Review.
-
FcER1: A Novel Molecule Implicated in the Progression of Human Diabetic Kidney Disease.Front Immunol. 2021 Dec 1;12:769972. doi: 10.3389/fimmu.2021.769972. eCollection 2021. Front Immunol. 2021. PMID: 34925339 Free PMC article.
-
Impact of treating the metabolic syndrome on chronic kidney disease.Nat Rev Nephrol. 2009 Sep;5(9):520-8. doi: 10.1038/nrneph.2009.114. Epub 2009 Jul 28. Nat Rev Nephrol. 2009. PMID: 19636332 Review.
-
Diagnostic Value of the Combined Measurement of Serum HCY and NRG4 in Type 2 Diabetes Mellitus with Early Complicating Diabetic Nephropathy.J Pers Med. 2023 Mar 20;13(3):556. doi: 10.3390/jpm13030556. J Pers Med. 2023. PMID: 36983737 Free PMC article.
-
Schisandrin C attenuates renal damage in diabetic nephropathy by regulating macrophage polarization.Am J Transl Res. 2021 Jan 15;13(1):210-222. eCollection 2021. Am J Transl Res. 2021. PMID: 33527019 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical